MagForce AG / Key word(s): Capital Increase
21.11.2014 09:30
Dissemination of a Corporate News, transmitted by DGAP - a service of EQS
Group AG.
The issuer / publisher is solely responsible for the content of this
announcement.
---------------------------------------------------------------------------
Not for release, publication or distribution in or into the United States,
Canada, Australia or Japan or any other jurisdiction in which offers or
sales would be prohibited by applicable laws.
MagForce AG Successfully Completes Capital Increase at a Price of EUR 6.00
per New Share
Proceeds will be Used to Accelerate Commercialization and to Broaden
Product Portfolio
Berlin, Germany, November 21, 2014 - The Management Board of MagForce AG
(Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading
medical device company in the field of nanomedicine focused on oncology,
has announced today that it has successfully placed 1,700,000 new shares at
EUR 6.00 per share against cash contribution with qualified investors
raising proceeds in the amount of EUR 10.2 million. New shares will be
issued utilizing a portion of the Authorized Capital (2013/III)
representing approx. 7 percent of the registered share capital.
Subscription rights of existing shareholders had been excluded.
The new shares were offered by Berenberg and Hauck & Aufhäuser
Privatbankiers, acting as Joint Bookrunners in a private placement by means
of an accelerated bookbuilding to qualified investors in Germany and
selected countries outside of the United States, Canada, Australia and
Japan.
The proceeds shall be utilized to accelerate the commercialization of
NanoTherm(TM) Therapy outside of North America, where MagForce AG already
has European regulatory approval for the treatment of Brain Tumors, and to
broaden the product portfolio with further development of next generation
nanoparticles. The next generation of nanoparticles provides for
temperature-dependent drug release and will significantly accelerate the
expansion of the treatment for other solid tumors such as Esophageal and
Pancreatic Cancers.
The new shares shall be included in the Open Market of the Frankfurt Stock
Exchange (Entry Standard), without publication of a prospectus, and are
entitled to dividends starting from January 1, 2014.
Ben Lipps, CEO and Chairman of the Board of MagForce, commented: "The
successful capital increase shows the continued trust and confidence
investors put into the MagForce technology and our team. Further
accelerating the commercialization of our NanoTherm(TM) Therapy and
broadening of our product portfolio will help MagForce to unveil the full
potential of its technology."
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(TM) therapy enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles. Mithril Capital
Management, a growth-stage technology fund founded by Ajay Royan and Peter
Thiel, along with MagForce AG, are investors and strategic partners in
MagForce USA, Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R),
and NanoActivator(R) are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com.
Disclaimer
This document neither constitutes an offer to sell nor a solicitation of an
offer to buy or subscribe for securities of MagForce AG. No public offering
of securities of MagForce AG will be made nor is a public offering
intended.
This document and the information contained therein may not be distributed
in or into the United States of America, Canada, Australia, Japan or any
other jurisdictions, in which such offeror such solicitation would be
prohibited. This document does not constitute an offer for the sale of of
securities in the United States.
The shares of MagForce AG may not be sold or offered for sale within the
United States or to or for the account or benefit of US Persons (as defined
in Regulation S under the U.S. Securities Act of 1933 as amended (the
"Securities Act")) unless they are registered under the Securities Act or
unless they are subject to an exemption from registration. Neither MagForce
AG nor any other person intend to register securities of MagForce AG or to
make a public offer of securities of MagForce AG in the United States.
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
Contact:
Anne Hennecke
MC Services AG
T +49 211 529252-22
F +49 211 529252-29
Email: anne.hennecke@mc-services.eu
21.11.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MagForce AG
Max-Planck-StraÃe 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Freiverkehr in Berlin, Düsseldorf, Stuttgart; Frankfurt in
Open Market (Entry Standard)
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: MagForce AG: MagForce AG Successfully Completes Capital Increase at a Price of EUR 6.00 per New Share
| Source: EQS Group AG